Automate Your Wheel Strategy on CING
With Tiblio's Option Bot, you can configure your own wheel strategy including CING - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CING
- Rev/Share 2957.6339
- Book/Share 1.2557
- PB 3.3447
- Debt/Equity 1.1941
- CurrentRatio 1.5184
- ROIC -1.4757
- MktCap 22111488.0
- FreeCF/Share -3.9709
- PFCF -1.2686
- PE -1.0268
- Debt/Assets 0.4887
- DivYield 0
- ROE -2.3216
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CING | ROTH MKM | -- | Buy | -- | $12 | Jan. 10, 2025 |
News
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Published: August 21, 2025 by: Newsfile Corp
Sentiment: Neutral
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 2Q25 results that highlight continued progress toward the commercial launch of its lead ADHD asset, CTx-1301.
Read More
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission
Read More
About Cingulate Inc. (CING)
- IPO Date 2021-12-08
- Website https://www.cingulate.com
- Industry Biotechnology
- CEO Shane J. Schaffer
- Employees 13